NCT02181517 - A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

Macular Degeneration

Interventions

DRUG

abicipar pegol

Abicipar pegol administered to the study eye by intravitreal injection at day 1, weeks 4 and 8.

DRUG

ranibizumab

Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.

OTHER

sham procedure

Sham procedure to the study eye at weeks 12 and 16.

Trial Locations (1)

Phoenix